1GLOBAL
7.5.2024 11:01:34 CEST | Business Wire | Press release
Germany's largest independent mobile service provider, freenet, has partnered with the global telecommunications network 1GLOBAL to power their new offering, freenet Travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506185419/en/
1GLOBAL provides roaming services to 7.5 million freenet customers. (Graphic: Business Wire)
This new product creates immediate added value for freenet customers who plan on visiting other countries. Whether travelling for business or leisure, calculating roaming costs and data usage abroad can often be complex. 1GLOBAL eSIMs offer millions of freenet customers a crucial advantage, enabling seamless mobile internet usage in countries outside the EU while avoiding high roaming charges.
"We are among the few providers worldwide capable of supplying and configuring eSIMs ourselves. Through this partnership, millions of freenet customers can now book various data packages for countries outside the EU, allowing them to communicate cost-effectively during their travels."
- Hakan Koç, founder and CEO of 1GLOBAL
1GLOBAL eSIMs: worry-free travel and minimal roaming charges for freenet users
All freenet customers with eSIM-compatible devices now have access to the service. To install the eSIM on their phone, they simply scan a QR code and follow the onscreen prompts. Once downloaded, a 1GLOBAL eSIM can be used as many times as needed in any of the countries supported by the secure high-speed network.
Users can choose from a variety of tariffs and instantly book a data plan for their desired destination, even if they have no internet connection. They will also benefit from 1GLOBAL’s high-speed 4G/5G network. 1GLOBAL has developed a complete eSIM ecosystem including Remote SIM Provisioning (RSP) and Entitlement Servers, ensuring the highest quality throughout the eSIM deployment lifecycle. Their fully integrable API can be customised and adapted to deliver an outstanding client experience across a wide range of telco products.
"By using 1GLOBAL eSIM capabilities, we are embracing a future-proof, modern technology. This enables us to further expand our positioning around digital lifestyle offerings."
- Salome Andrade Pohl, Head of Digital Lifestyle at freenet
About 1GLOBAL
1GLOBAL provides quick and secure mobile network connectivity in over 160 countries worldwide. 1GLOBAL eSIM technology seamlessly integrates into third-party apps and products, and can be installed on any eSIM-compatible mobile device in less than a minute.
Founded in 2022, 1GLOBAL is the new startup of Hakan Koç, co-founder and former co-CEO of AUTO1 Group. 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised, GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and have been granted fully regulated MVNO (mobile virtual network operators) status in nine of them.
About freenet
Freenet offers a comprehensive portfolio of mobile communications, internet, and TV entertainment services. Customers can find the ideal products for their digital life in approximately 500 freenet stores and online at www.freenet-mobilfunk.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185419/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom